Immuneering (IMRX) Consolidated Net Income: 2020-2023
Historic Consolidated Net Income for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$54.8 million.
- Immuneering's Consolidated Net Income fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
- Immuneering's Consolidated Net Income amounted to -$54.8 million in FY2023, which was down 8.50% from -$50.5 million recorded in FY2022.
- Immuneering's 5-year Consolidated Net Income high stood at -$17.0 million for FY2020, and its period low was -$54.8 million during FY2023.
- Moreover, its 3-year median value for Consolidated Net Income was -$50.5 million (2022), whereas its average is -$46.3 million.
- Data for Immuneering's Consolidated Net Income shows a maximum YoY tumbled of 96.81% (in 2021) over the last 5 years.
- Over the past 4 years, Immuneering's Consolidated Net Income (Yearly) stood at -$17.0 million in 2020, then tumbled by 96.81% to -$33.5 million in 2021, then slumped by 50.63% to -$50.5 million in 2022, then decreased by 8.50% to -$54.8 million in 2023.